NO20042173L - Fremgangsmate for fremstilling av rekombinant polypeptid - Google Patents

Fremgangsmate for fremstilling av rekombinant polypeptid

Info

Publication number
NO20042173L
NO20042173L NO20042173A NO20042173A NO20042173L NO 20042173 L NO20042173 L NO 20042173L NO 20042173 A NO20042173 A NO 20042173A NO 20042173 A NO20042173 A NO 20042173A NO 20042173 L NO20042173 L NO 20042173L
Authority
NO
Norway
Prior art keywords
preparation
recombinant polypeptide
polypeptide
recombinant
Prior art date
Application number
NO20042173A
Other languages
English (en)
Inventor
Jorg Windisch
Renate Kunert
Kurt Schorgendorfer
Florian Untergluggauer
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23304597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042173(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of NO20042173L publication Critical patent/NO20042173L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
NO20042173A 2001-11-28 2004-05-26 Fremgangsmate for fremstilling av rekombinant polypeptid NO20042173L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33386801P 2001-11-28 2001-11-28
PCT/EP2002/013297 WO2003046187A1 (en) 2001-11-28 2002-11-26 Method for producing a recombinant polypeptide

Publications (1)

Publication Number Publication Date
NO20042173L true NO20042173L (no) 2004-08-11

Family

ID=23304597

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042173A NO20042173L (no) 2001-11-28 2004-05-26 Fremgangsmate for fremstilling av rekombinant polypeptid

Country Status (19)

Country Link
US (1) US20050084969A1 (no)
EP (1) EP1453966B1 (no)
JP (1) JP4723185B2 (no)
KR (1) KR20040063937A (no)
CN (1) CN1596310A (no)
AU (1) AU2002358047A1 (no)
BR (1) BR0214489A (no)
CA (1) CA2468832A1 (no)
HR (1) HRP20040477A2 (no)
HU (1) HUP0500059A2 (no)
IL (1) IL161909A0 (no)
MX (1) MXPA04005191A (no)
NO (1) NO20042173L (no)
NZ (1) NZ533133A (no)
PL (1) PL370550A1 (no)
RU (1) RU2004119814A (no)
SI (1) SI1453966T1 (no)
WO (1) WO2003046187A1 (no)
ZA (1) ZA200403802B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264710A1 (en) * 2003-10-09 2007-11-15 Hyea-Kyung Ahn Process for Purifying Human Thrombopoietin with High Content of Sialic Acid
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP2592147A1 (en) 2007-10-12 2013-05-15 F. Hoffmann-La Roche AG Protein expression from multiple nucleic acids
WO2012077128A1 (en) * 2010-12-07 2012-06-14 Intas Biopharmaceuticals Limited A novel cell line development process to produce recombinant proteins using twin vector expression system
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014138921A1 (en) * 2013-03-15 2014-09-18 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
JP6050289B2 (ja) * 2013-07-11 2016-12-21 Jcrファーマ株式会社 組換え蛋白質高発現細胞株の選択法
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ756132A (en) 2017-03-10 2022-02-25 Hoffmann La Roche Method for producing multispecific antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
DE3624453A1 (de) * 1986-07-19 1988-01-28 Behringwerke Ag Verfahren zur herstellung von humanem antithrombin iii (atiii), dafuer geeignete vektoren und wirtszellen, so erhaltenes, biologisch aktives atiii und dieses enthaltende arzneimittel
EP0319206A3 (en) * 1987-11-30 1990-04-18 Berlex Laboratories, Inc. Gene amplification
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
US20050084969A1 (en) 2005-04-21
SI1453966T1 (sl) 2012-11-30
HRP20040477A2 (en) 2005-06-30
EP1453966A1 (en) 2004-09-08
CN1596310A (zh) 2005-03-16
JP2005510242A (ja) 2005-04-21
WO2003046187A1 (en) 2003-06-05
HUP0500059A2 (hu) 2005-04-28
ZA200403802B (en) 2005-07-01
JP4723185B2 (ja) 2011-07-13
NZ533133A (en) 2006-02-24
AU2002358047A1 (en) 2003-06-10
MXPA04005191A (es) 2005-04-29
KR20040063937A (ko) 2004-07-14
EP1453966B1 (en) 2012-07-11
IL161909A0 (en) 2005-11-20
BR0214489A (pt) 2004-10-19
PL370550A1 (en) 2005-05-30
RU2004119814A (ru) 2005-04-20
CA2468832A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
NO20042173L (no) Fremgangsmate for fremstilling av rekombinant polypeptid
HRP20040476A2 (en) Chromatographic purification of recombinant human erythropoietin
AU2002310321A8 (en) Compositions and methods for high-level, large-scale production of recombinant proteins
HK1066468A1 (en) Aqueous sustained-release formulations of proteins
DK1417234T3 (da) Rekombinante anti-plasmodium falciparum antistoffer
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
AU2002237195A1 (en) Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
EP1441030A4 (en) METHOD OF PURIFYING RECOMBINANT FUSED PROTEIN AND PROTEIN PRODUCTION PROCESS USING THE PURIFICATION PROCESS
NO20023445L (no) Fremgangsmåte for fremstilling av peptider
PL370082A1 (en) Novel immunogenic mimetics of multimer proteins
AU2002300166A1 (en) Process for the Preparation of Peptides
GB2392445B (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
FR2846659B1 (fr) Fragments peptidiques du facteur harp inhibant l'angiogenese
EP1451367A4 (en) GENE OF LEADING PEPTIDES FOR SECRETING RECOMBINANT PROTEINS IN BACTERIA
NO20041563L (no) Rensemetode for polypeptid
EP1423402A4 (en) NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE
SI1656455T1 (sl) Postopek za čiščenje rekombinantnih polipeptidov
AU2002342858A1 (en) Human high-affinity antibody fragments for essential proteins of the hepatitis-c virus
PL367835A1 (en) Use of polyclonal immunoglobulins as vaccine
AU2003226907A8 (en) Method for the preparation of recombinant mammalian heparin-binding protein (hbp)
AU5603201A (en) Co-expression of recombinant proteins
EP1385979A4 (en) METHOD FOR IMPROVING THE TRANSLATION AND EXPRESSION OF RECOMBINANT PROTEINS
EP1434874A4 (en) IMMUNOAFFINITY ISOLATION OF MODIFIED PEPTIDES FROM COMPLEX MIXTURES
AU2002353431A8 (en) Method of modification of a protein or polypeptide
AU2002356599A1 (en) Production of recombinant antibodies by means of fusion with elastin-like peptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application